{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:32:39Z","timestamp":1790728359915,"version":"4.1.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Long-term multiple myeloma therapy by immunomodulatory drugs (IMiDs) raises the question of management of adverse effects. The aim of this study is to assess the impact of an educational session for patients on the acquisition of knowledge to manage hematologic and thromboembolic adverse effects of IMiDs. In this prospective single-center study, patients attended an educational session with a hospital clinical pharmacist and a nurse. The primary endpoint was the patient\u2019s level of knowledge for the management of IMiDs adverse effects, assess with a dedicated questionnaire administered before the session then 1 and 6 months after. Assessment of knowledge was combined with self-assessment of certainty. The secondary endpoints were adherence and IMiD treatment satisfaction. 50 patients were included. Patient knowledge increased at 1 month (p&lt;0.001) despite a loss of knowledge at 6 months (p&lt;0.05). Six months after the educational intervention, the number of patients with skills considered satisfactory by the pharmacist and nurse increased (p&lt;0.01). Most patients showed satisfactory adherence, with medication possession ratio \u2265 80%. The Self CARe and MEdication Toxicity (SCARMET) study highlighted the impact of multidisciplinary follow-up in multiple myeloma patients to improve knowledge of toxicity self-management.<\/jats:p>","DOI":"10.1371\/journal.pone.0243309","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T21:07:14Z","timestamp":1607116034000},"page":"e0243309","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients\u2019 knowledge to manage adverse effects"],"prefix":"10.1371","volume":"15","author":[{"given":"Juliette","family":"P\u00e9richou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-4231","authenticated-orcid":true,"given":"Florence","family":"Ranchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Herledan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Larbre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lazareth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Beny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Vantard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9rane","family":"Schwiertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Gaelle","family":"Caffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Brisou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"pone.0243309.ref001","unstructured":"Myeloma\u2014Cancer Stat Facts. SEER n.d. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html (accessed December 3, 2018)."},{"key":"pone.0243309.ref002","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"A Palumbo","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"pone.0243309.ref003","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2017.72.2447","article-title":"Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma","volume":"35","author":"AJ Olszewski","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"pone.0243309.ref004","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/PPA.S106629","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature","volume":"10","author":"D Eek","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"pone.0243309.ref005","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"M Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"pone.0243309.ref006","first-page":"269","article-title":"Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies","volume":"5","author":"S Blumel","year":"2014","journal-title":"J Adv Pract Oncol"},{"key":"pone.0243309.ref007","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/10428194.2014.915544","article-title":"Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone","volume":"56","author":"HL Sun","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"pone.0243309.ref008","first-page":"36","article-title":"S\u00e9curisation de l\u2019emploi des chimioth\u00e9rapies anticanc\u00e9reuses administrables par voie orale","volume":"44","author":"F Ranchon","year":"2009","journal-title":"Pharm Hosp"},{"key":"pone.0243309.ref009","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jgo.2017.04.005","article-title":"Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer","volume":"8","author":"G Nightingale","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"pone.0243309.ref010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"K Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"pone.0243309.ref011","doi-asserted-by":"crossref","first-page":"e0214446","DOI":"10.1371\/journal.pone.0214446","article-title":"Adherence to immunomodulatory drugs in patients with multiple myeloma","volume":"14","author":"A Cransac","year":"2019","journal-title":"PLOS ONE"},{"key":"pone.0243309.ref012","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1007\/s00520-019-04721-4","article-title":"High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology\/oncology group practices in Germany","volume":"27","author":"S Feiten","year":"2019","journal-title":"Support Care Cancer"},{"key":"pone.0243309.ref013","first-page":"140","article-title":"Consultations pharmaceutiques chez des patients trait\u00e9s par chimioth\u00e9rapie orale","volume":"35","author":"A Laugueux","year":"2016","journal-title":"J Pharm Clin"},{"key":"pone.0243309.ref014","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1051\/tpe\/2012017","article-title":"Observance th\u00e9rapeutique aux antir\u00e9troviraux et \u00e9valuations p\u00e9dagogiques des programmes d\u2019\u00e9ducation th\u00e9rapeutique: pas de corr\u00e9lation syst\u00e9matique. \u00c0 propos d\u2019un cas","volume":"5","author":"F Pasquier","year":"2013","journal-title":"Educ Th\u00e9rapeutique Patient\u2014Ther Patient Educ"},{"key":"pone.0243309.ref015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1051\/tpe\/2010004","article-title":"Recueil de pratiques visant \u00e0 harmoniser les \u00e9valuations p\u00e9dagogiques des comp\u00e9tences de soins chez les enfants de 9\u201311 ans en surpoids ou ob\u00e8ses","volume":"2","author":"S Videau","year":"2010","journal-title":"Educ Th\u00e9rapeutique Patient\u2014Ther Patient Educ"},{"key":"pone.0243309.ref016","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pec.2004.01.001","article-title":"Adjusting insulin doses: from knowledge to decision","volume":"56","author":"G Reach","year":"2005","journal-title":"Patient Educ Couns"},{"key":"pone.0243309.ref017","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1051\/tpe\/2009017","article-title":"La connaissance partielle chez le patient: pourquoi et comment la mesurer","volume":"1","author":"D. Leclercq","year":"2009","journal-title":"Educ Th\u00e9rapeutique Patient\u2014Ther Patient Educ"},{"key":"pone.0243309.ref018","first-page":"276","article-title":"Relationship between patient practice-oriented knowledge and metabolic control in intensively treated Type 1 diabetic patients: results of the validation of the Knowledge and Practices Diabetes Questionnaire","volume":"13","author":"A Nicolucci","year":"2000","journal-title":"Diabetes Nutr Metab"},{"key":"pone.0243309.ref019","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"JA Cramer","year":"2008","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"pone.0243309.ref020","article-title":"An overview of the common methods used to measure treatment adherence","author":"LA Anghel","year":"2019","journal-title":"Med Pharm Rep"},{"key":"pone.0243309.ref021","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1524-4733.2008.00323.x","article-title":"Development and validation of the \u201cTreatment Satisfaction with Medicines Questionnaire\u201d (SATMED-Q)","volume":"11","author":"MA Ruiz","year":"2008","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"pone.0243309.ref022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jval.2012.08.2224","article-title":"Detecting changes in patient treatment satisfaction with medicines: the SATMED-Q","volume":"16","author":"J Rejas","year":"2013","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"pone.0243309.ref023","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1200\/JCO.2008.20.6755","article-title":"Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial.","volume":"27","author":"A Molassiotis","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"pone.0243309.ref024","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1200\/JCO.2007.15.2322","article-title":"Does age really matter? Recall of information presented to newly referred patients with cancer","volume":"26","author":"J Jansen","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"pone.0243309.ref025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00277-017-3191-7","article-title":"Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?","volume":"97","author":"X Leleu","year":"2018","journal-title":"Ann Hematol"},{"key":"pone.0243309.ref026","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00520-009-0692-5","article-title":"Development of the MASCC teaching tool for patients receiving oral agents for cancer","volume":"18","author":"S Kav","year":"2010","journal-title":"Support Care Cancer"},{"key":"pone.0243309.ref027","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/geront\/45.4.545","article-title":"Improving medication knowledge among older adults with heart failure: a patient-centered approach to instruction design","volume":"45","author":"DG Morrow","year":"2005","journal-title":"The Gerontologist"},{"key":"pone.0243309.ref028","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1191\/026921601680419429","article-title":"Receiving a diagnosis of lung cancer: patients\u2019 interpretations, perceptions and perspectives","volume":"15","author":"SJ Yardley","year":"2001","journal-title":"Palliat Med"},{"key":"pone.0243309.ref029","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/2347-5625.135820","article-title":"Effects of nurse-led telephone follow-up for discharged patients treated with chemotherapy","volume":"1","author":"G Li","year":"2014","journal-title":"Asia-Pac J Oncol Nurs"},{"key":"pone.0243309.ref030","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/pon.3956","article-title":"A randomized controlled pilot trial of a Web-based resource to improve cancer knowledge in adolescent and young adult survivors of childhood cancer","volume":"25","author":"A Kunin-Batson","year":"2016","journal-title":"Psychooncology"},{"key":"pone.0243309.ref031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0738-3991(02)00226-4","article-title":"The use of degrees of certainty to evaluate knowledge","volume":"51","author":"D Bruttomesso","year":"2003","journal-title":"Patient Educ Couns"},{"key":"pone.0243309.ref032","doi-asserted-by":"crossref","first-page":"e56247","DOI":"10.1371\/journal.pone.0056247","article-title":"Comparison between Two Generic Questionnaires to Assess Satisfaction with Medication in Chronic Diseases","volume":"8","author":"S Delestras","year":"2013","journal-title":"PLoS ONE"},{"key":"pone.0243309.ref033","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment","volume":"318","author":"E Basch","year":"2017","journal-title":"JAMA"},{"key":"pone.0243309.ref034","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"L Eliasson","year":"2011","journal-title":"Leuk Res"},{"key":"pone.0243309.ref035","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/cncr.22355","article-title":"Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. A pilot study of telephone-based coping skills training","volume":"109","author":"LC Campbell","year":"2007","journal-title":"Cancer"},{"key":"pone.0243309.ref036","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/NCC.0b013e3182551587","article-title":"An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study","volume":"36","author":"SL Spoelstra","year":"2013","journal-title":"Cancer Nurs"},{"key":"pone.0243309.ref037","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF02850081","article-title":"Medication adherence and persistence: a comprehensive review","volume":"22","author":"KP Krueger","year":"2005","journal-title":"Adv Ther"},{"key":"pone.0243309.ref038","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"L Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"pone.0243309.ref039","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"S Karve","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"pone.0243309.ref040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3111\/13696998.2015.1130710","article-title":"A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma","volume":"19","author":"C Lee","year":"2016","journal-title":"J Med Econ"},{"key":"pone.0243309.ref041","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"L Noens","year":"2009","journal-title":"Blood"},{"key":"pone.0243309.ref042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000366226","article-title":"Adherence and Patients\u2019 Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies","volume":"88","author":"P Barth\u00e9l\u00e9my","year":"2015","journal-title":"Oncology"},{"key":"pone.0243309.ref043","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0277-9536(97)00128-7","article-title":"Patient satisfaction: A review of issues and concepts","volume":"45","author":"J Sitzia","year":"1997","journal-title":"Soc Sci Med"},{"key":"pone.0243309.ref044","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1200\/JOP.2016.019729","article-title":"Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer","volume":"13","author":"JM Jacobs","year":"2017","journal-title":"J Oncol Pract"},{"key":"pone.0243309.ref045","doi-asserted-by":"crossref","first-page":"e1485","DOI":"10.1111\/jocn.14270","article-title":"Effectiveness of a patient education plan on knowledge of post-op venous thromboembolism survival skills","volume":"27","author":"J Green","year":"2018","journal-title":"J Clin Nurs"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T21:08:06Z","timestamp":1607116086000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243309"}},"subtitle":[],"editor":[{"given":"Vijayaprakash","family":"Suppiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0243309","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}